title: Lixivaptan for hyponatremia--the numbers game.
authors.affiliation: Denver Health Hospital and Authority, Department of Internal Medicine, Denver, Colorado, USA. ryan.borne@dhha.org
authors.forename: Ryan T
authors.initials: RT
authors.lastname: Borne
authors.forename: Mori J
authors.initials: MJ
authors.lastname: Krantz
mesh_terms: D065092:Antidiuretic Hormone Receptor Antagonists; D001549:Benzamides / Q000009:adverse effects* / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D003627:Data Interpretation, Statistical; D017277:Drug Approval; D006333:Heart Failure / Q000097:blood / Q000150:complications / Q000401:mortality / Q000503:physiopathology; D006801:Humans; D007010:Hyponatremia / Q000188:drug therapy* / Q000209:etiology; D007902:Length of Stay; D011758:Pyrroles / Q000009:adverse effects* / Q000627:therapeutic use*; D012306:Risk; D012720:Severity of Illness Index; D012964:Sodium / Q000097:blood; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration; D001569:Benzodiazepines
chemical_list: D065092:Antidiuretic Hormone Receptor Antagonists; D001549:Benzamides; D015415:Biomarkers; D011758:Pyrroles; D012964:Sodium; C409452:lixivaptan; D001569:Benzodiazepines